by Barry101 | Sep 19, 2022 | Press Release, Uncategorized
Highlights Significant Progress Made in Recent Years – and Especially Over Past 18 Months – in Repurposing Lead Drug Ampligen in Oncology to Benefit Patients and All Shareholders Calls on Shareholders to Support Continued Positive Momentum by Re-Electing...
by Barry101 | Sep 7, 2022 | Press Release, Uncategorized
OCALA, Fla., Sept. 07, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...
by Barry101 | Sep 6, 2022 | Press Release, Uncategorized
OCALA, Fla., Sept. 06, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...
by Barry101 | Aug 30, 2022 | Press Release, Uncategorized
Phase 2 to evaluate polarized dendritic cell vaccine, interferon alpha-2b, Ampligen and celecoxib for the treatment of HLA-A2+ refractory melanoma First patient dosing is expected in Q4, 2022 OCALA, Fla., Aug. 30, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM)...
by Barry101 | Aug 18, 2022 | Press Release, Uncategorized
Company receives IRB approval of study protocol Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with locally advanced pancreatic cancer OCALA, Fla., Aug. 18, 2022 — AIM...
